Home >> Research Area >>Apoptosis>>Bcl-2 Family>> Radotinib(IY-5511)

Radotinib(IY-5511)

Bcl-Abl tyrosine kinase inhibitor CAS# 926037-48-1

Radotinib(IY-5511)

2D Structure

Catalog No. BCC6398----Order now to get a substantial discount!

Product Name & Size Price Stock
Radotinib(IY-5511): 5mg $81 In Stock
Radotinib(IY-5511): 10mg Please Inquire In Stock
Radotinib(IY-5511): 20mg Please Inquire Please Inquire
Radotinib(IY-5511): 50mg Please Inquire Please Inquire
Radotinib(IY-5511): 100mg Please Inquire Please Inquire
Radotinib(IY-5511): 200mg Please Inquire Please Inquire
Radotinib(IY-5511): 500mg Please Inquire Please Inquire
Radotinib(IY-5511): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Radotinib(IY-5511)

3D structure

Package In Stock

Radotinib(IY-5511)

Number of papers citing our products

Chemical Properties of Radotinib(IY-5511)

Cas No. 926037-48-1 SDF Download SDF
PubChem ID 16063245 Appearance Powder
Formula C27H21F3N8O M.Wt 530.5
Type of Compound N/A Storage Desiccate at -20°C
Solubility >26.6mg/mL in DMSO
Chemical Name 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=NC=CN=C5
Standard InChIKey DUPWHXBITIZIKZ-UHFFFAOYSA-N
Standard InChI InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Radotinib(IY-5511) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Radotinib(IY-5511) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Radotinib(IY-5511)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.885 mL 9.4251 mL 18.8501 mL 37.7003 mL 47.1254 mL
5 mM 0.377 mL 1.885 mL 3.77 mL 7.5401 mL 9.4251 mL
10 mM 0.1885 mL 0.9425 mL 1.885 mL 3.77 mL 4.7125 mL
50 mM 0.0377 mL 0.1885 mL 0.377 mL 0.754 mL 0.9425 mL
100 mM 0.0189 mL 0.0943 mL 0.1885 mL 0.377 mL 0.4713 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Radotinib(IY-5511)

Radotinib(IY-5511) is a novel and selective Bcl-Abl tyrosine kinase inhibitor. [1]

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

In vitro, radotinib couples to Bcr-Abl and reduce the phosphorylation of Bcr-Abl target protein CrkL. The pre-clinical studies shows superiority of radotinib to imatinib in both wild-type and mutant BCR-ABL1 positive CML cell lines. [1]

In a phase I clinical trial, dose up to 1000 mg/day of radotinib exhibits no dose-limiting toxicities. Phase II study proves radotinib to be an effective and well tolerated in chronic phase-chronic myeloid leukemia patients with resistance and/or intolerance to Bcr-Abl1 tyrosine kinase inhibitors. [1]

Reference:
1.  Kim SH, Menon H, Jootar S et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6.

Featured Products
New Products
 

Keywords:

Radotinib(IY-5511),926037-48-1,Natural Products,Bcl-2 Family, buy Radotinib(IY-5511) , Radotinib(IY-5511) supplier , purchase Radotinib(IY-5511) , Radotinib(IY-5511) cost , Radotinib(IY-5511) manufacturer , order Radotinib(IY-5511) , high purity Radotinib(IY-5511)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: